Status:
COMPLETED
Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
40+ years
Phase:
PHASE1
PHASE2
Brief Summary
Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting anti-inflammatory and anti-fibrotic properties in vitro and in vivo. Somatostatin receptors are increased ...
Eligibility Criteria
Inclusion
- confident diagnosis of IPF according to ATS/ERS criteria
Exclusion
- known intolerance to somatostatin or octreotide
- another disease with predicted survival \< 12 months
- pregnancy or lactation
- previous treatment with somatostatin or somatostatin analogs
- patient on a waiting list for transplantation
- antifibrotic treatment or prednisone \> 10 mg/day within the last 6 weeks
- symptomatic biliary lithiasis
- blood coagulation disorders that prevent intra-muscular injections
- HIV infection
- hepatitis B or C active infection
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00463983
Start Date
October 1 2006
End Date
January 1 2012
Last Update
March 5 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Pneumologie Hôpital Avicenne 125 rue de Stalingrad
Bobigny, France, 93009
2
Service de Pneumologie Hôpital Ambroise Paré
Boulogne-Billancourt, France, 92100
3
Service de Pneumologie Hôpital Côte de Nacre
Caen, France, 14000
4
Service de Pneumologie Hôpital Antoine Béclère
Clamart, France, 92140